Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.
about
Pelvic mass associated with raised CA 125 for benign condition: a case reportHE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseasesIn 2014, can we do better than CA125 in the early detection of ovarian cancer?The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomasProteomics of ovarian cancer: functional insights and clinical applicationsIdentification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancerComparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal massesThe significance and robustness of a plasma free amino acid (PFAA) profile-based multiplex function for detecting lung cancer.Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese womenA preliminary candidate approach identifies the combination of chemerin, fetuin-A, and fibroblast growth factors 19 and 21 as a potential biomarker panel of successful aging.M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patientsComparison of specific ovarian tumor markers by elecsys analyzer 2010Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer managementEvaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass.Urinary Neutrophil Gelatinase-Associated Lipocalin Measured on Admission to the Intensive Care Unit Accurately Discriminates between Sustained and Transient Acute Kidney Injury in Adult Critically Ill PatientsMultianalyte assay systems in the differential diagnosis of ovarian cancer.Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women.Serum biomarker profiles as diagnostic tools in lung cancer.-The advancement of biomarker-based diagnostic tools for ovarian, breast, and pancreatic cancer through the use of urine as an analytical biofluid.Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkersOverexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance.Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.Combined detection of serum matrix metalloproteinase 9, acetyl heparinase and cathepsin L in diagnosis of ovarian cancer.Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic massSignificance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ.Biomarker testing for ovarian cancer: clinical utility of multiplex assaysAssessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic massThe use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer.Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancerSerum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer.Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer.Translational Research and Plasma Proteomic in Cancer.The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review.
P2860
Q24630815-055E5B64-7320-4C93-80B9-0502BFB0C300Q24634978-B170000C-8EC5-4775-A5C9-01E62EAA5C6FQ26825152-96894547-9606-4A42-95DC-D31DC55DEEA6Q26992102-47C0A09F-9317-4FB8-8387-7500B0BD33E3Q28082632-8E7E8911-D882-4443-83FF-05071725A875Q28478197-CC98D839-6884-4ACB-A85D-9C0E04B7C05DQ33733786-9C2677F6-69D2-4198-8DA0-FC496370F2F2Q33777586-F48BA309-96F5-40EF-910B-E53167DFC277Q33918256-66C1812B-F913-4A57-AC39-549122B8DD54Q34587180-D9B36AC7-AD84-479A-B248-1DC22F55C6B2Q34738849-E9F48E15-5B97-40EE-8323-073B7402BA79Q35021181-51CB8BE9-705C-44C7-A4C2-7206D87169DAQ35126762-FC0C3FA9-CFFD-45CD-AC19-BEA7C638D5A5Q35537498-390BCB23-BDFD-4FB5-98AD-DA1B62503074Q35589339-A603F43A-54BF-4F74-9FEE-AA0013280A0EQ35601405-6AA88F04-013C-4693-8464-DD836EF1742DQ35612779-950EEEFD-D574-4816-BCE9-FE3CE8562120Q35663640-E2B2A152-F45D-4334-ADBC-C26FD260A62DQ35791780-8068091A-394E-4AEE-9AF5-E6C56AB3E77EQ35854476-B05F6588-464A-4093-B89B-A98F849EC1B6Q35922723-32D748C0-11D3-40F5-8A8C-B45001DD4A4FQ36016138-3EF97E36-6341-449D-BA31-B1813B737A99Q36016842-D1DD10C8-ADC0-4EEB-9496-C733E6DCA980Q36076953-4B015E31-43A1-444C-A7AB-F386B75D6BB6Q36286844-C0EAD1C7-660F-4FEF-9BF1-0731D9EECC67Q36385490-72DF0578-07CE-4064-AD21-1D58028DAF8FQ36563111-5E0212F9-3C71-4FAB-906D-C73D2D51DD33Q36674049-A8B70AFF-9D8D-4C0C-B75D-6F3D81C12016Q36752512-5C9C6C67-3D4B-4697-8013-18D3D85A85FFQ36797835-CD8FB971-718F-43F9-A892-B2EE072F383DQ36897149-A20B5CB9-2E0A-4A42-B0C8-46BFB142098DQ36904090-011373BA-BDF1-45C5-9842-C636F822A3E2Q36982622-597DE705-39AA-4B9D-892B-9B94997A3E5AQ37093435-EF227826-B6F8-4E8E-994F-DF85D94921A2Q37297487-196BBEFF-B19D-49BB-840D-55AEE2066BC2Q37701232-ADBD2891-344D-49C8-A817-E500C131C6E3Q37703442-2AE0CA60-D54A-4FA4-A496-F4E1625927DAQ38388103-59AF603E-1522-4175-9C2B-437ABFEF1719Q38610869-8DA34F79-6776-4AEF-9300-83C622ACC1BDQ38653169-A7134B2D-1329-465D-995E-63E04DB8F04C
P2860
Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Serum biomarker panels for the ...... patients with an adnexal mass.
@ast
Serum biomarker panels for the ...... patients with an adnexal mass.
@en
type
label
Serum biomarker panels for the ...... patients with an adnexal mass.
@ast
Serum biomarker panels for the ...... patients with an adnexal mass.
@en
prefLabel
Serum biomarker panels for the ...... patients with an adnexal mass.
@ast
Serum biomarker panels for the ...... patients with an adnexal mass.
@en
P2093
P2860
P1433
P1476
Serum biomarker panels for the ...... patients with an adnexal mass.
@en
P2093
Adele Marrangoni
Aleksey Lomakin
Anna Lokshin
Brian Nolen
Koen De Geest
Liudmila Velikokhatnaya
P2860
P304
P356
10.1016/J.YGYNO.2010.02.005
P407
P577
2010-03-24T00:00:00Z